Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-3100 for HPV-associated CIN 2/3
NCT01304524Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Apr 2011
- Primary completion
- May 2014
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 9
01
Overview
A Phase 2 trial of bizalimogene ralaplasmid in cervical intraepithelial neoplasia (CIN), sponsored by Inovio Pharmaceuticals, Inc.. Started Apr 2011; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT01304524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01304524.